Incidence, risk factors, and outcomes of second neoplasms in
patients with acute promyelocytic leukemia: the PETHEMA-PALG
experience

J 2024

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

SOBAS, Marta, Wanda KNOPINSKA-POSLUSZNY, Beata PIATKOWSKA-JAKUBAS, Flor GARCIA-ALVAREZ, Maria Elena Amutio DIEZ et. al.

Basic information

Original name

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

Authors

SOBAS, Marta (guarantor), Wanda KNOPINSKA-POSLUSZNY, Beata PIATKOWSKA-JAKUBAS, Flor GARCIA-ALVAREZ, Maria Elena Amutio DIEZ, Mar CABALLERO, David MARTINEZ-CUADRON, Eliana AGUIAR, Jose GONZALEZ-CAMPOS, Ana GARRIDO, Lorenzo ALGARRA, Olga SALAMERO, de la Serna JAVIER, Maria Jose SAYAS, Manuel Mateo PEREZ-ENCINAS, Susana VIVES, Belen VIDRIALES, Jorge LABRADOR, Ana Ines PRADO, Lucia CELEBRIN, Jiří MAYER (203 Czech Republic, belonging to the institution), Joana BRIOSO, de Laiglesia ALMUDENA, Juan Miguel BERGUA, Maria Luz AMIGO, Carlos RODRIGUEZ-MEDINA, Marta POLO, Agnieszka PLUTA, Edyta CICHOCKA, Marek SKARUPSKI, Miguel A SANZ, Agnieszka WIERZBOWSKA and Pau MONTESINOS

Edition

Annals of hematology, New York, Springer Verlag, 2024, 0939-5555

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.500 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s00277-023-05582-y

UT WoS

001126677700001

Keywords in English

Acute promyelocytic leukemia; Second neoplasms; Chemotherapy based and chemotherapy free regimens; Risk factors; Outcomes

Abstract

V originále

The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs). We performed a retrospective analysis of 2670 unselected APL patients, treated with PETHEMA "chemotherapy based" and "chemotherapy free" protocols. Only de novo APL patients who achieved complete remission (CR) and completed the three consolidation cycles were enrolled into the analysis. Out of 2670 APL patients, there were 118 (4.4%) who developed s-NPLs with the median latency period (between first CR and diagnosis of s-NPL) of 48.0 months (range 2.8-231.1): 43.3 (range: 2.8-113.9) for s-MDS/AML and 61.7 (range: 7.1-231.1) for solid tumour. The 5-year CI of all s-NPLs was of 4.43% and 10 years of 7.92%. Among s-NPLs, there were 58 cases of s-MDS/AML, 3 cases of other hematological neoplasms, 57 solid tumours and 1 non-identified neoplasm. The most frequent solid tumour was colorectal, lung and breast cancer. Overall, the 2-year OS from diagnosis of s-NPLs was 40.6%, with a median OS of 11.1 months. Multivariate analysis identified age of 35 years (hazard ratio = 0.2584; p < 0.0001) as an independent prognostic factor for s-NPLs. There were no significant differences in CI of s-NPLs at 5 years between chemotherapy-based vs chemotherapy-free regimens (hazard ratio = 1.09; p = 0.932). Larger series with longer follow-up are required to confirm the potential impact of ATO+ATRA regimens to reduce the incidence of s-NPLs after front-line therapy for APL.

Citovat

SOBAS, Marta, Wanda KNOPINSKA-POSLUSZNY, Beata PIATKOWSKA-JAKUBAS, Flor GARCIA-ALVAREZ, Maria Elena Amutio DIEZ, Mar CABALLERO, David MARTINEZ-CUADRON, Eliana AGUIAR, Jose GONZALEZ-CAMPOS, Ana GARRIDO, Lorenzo ALGARRA, Olga SALAMERO, de la Serna JAVIER, Maria Jose SAYAS, Manuel Mateo PEREZ-ENCINAS, Susana VIVES, Belen VIDRIALES, Jorge LABRADOR, Ana Ines PRADO, Lucia CELEBRIN, Jiří MAYER, Joana BRIOSO, de Laiglesia ALMUDENA, Juan Miguel BERGUA, Maria Luz AMIGO, Carlos RODRIGUEZ-MEDINA, Marta POLO, Agnieszka PLUTA, Edyta CICHOCKA, Marek SKARUPSKI, Miguel A SANZ, Agnieszka WIERZBOWSKA and Pau MONTESINOS. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience. Annals of hematology. New York: Springer Verlag, 2024, vol. 103, No 2, p. 451-461. ISSN 0939-5555. Available from: https://dx.doi.org/10.1007/s00277-023-05582-y.

@article{2371843,
   author = {Sobas, Marta and KnopinskaandPosluszny, Wanda and PiatkowskaandJakubas, Beata and Garciaandalvarez, Flor and Diez, Maria Elena Amutio and Caballero, Mar and MartinezandCuadron, David and Aguiar, Eliana and GonzalezandCampos, Jose and Garrido, Ana and Algarra, Lorenzo and Salamero, Olga and Javier, de la Serna and Sayas, Maria Jose and PerezandEncinas, Manuel Mateo and Vives, Susana and Vidriales, Belen and Labrador, Jorge and Prado, Ana Ines and Celebrin, Lucia and Mayer, Jiří and Brioso, Joana and Almudena, de Laiglesia and Bergua, Juan Miguel and Amigo, Maria Luz and RodriguezandMedina, Carlos and Polo, Marta and Pluta, Agnieszka and Cichocka, Edyta and Skarupski, Marek and Sanz, Miguel A and Wierzbowska, Agnieszka and Montesinos, Pau},
   article_location = {New York},
   article_number = {2},
   doi = {http://dx.doi.org/10.1007/s00277-023-05582-y},
   keywords = {Acute promyelocytic leukemia; Second neoplasms; Chemotherapy based and chemotherapy free regimens; Risk factors; Outcomes},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience},
   url = {https://link.springer.com/article/10.1007/s00277-023-05582-y},
   volume = {103},
   year = {2024}
}

TY  - JOUR
ID  - 2371843
AU  - Sobas, Marta - Knopinska-Posluszny, Wanda - Piatkowska-Jakubas, Beata - Garcia-alvarez, Flor - Diez, Maria Elena Amutio - Caballero, Mar - Martinez-Cuadron, David - Aguiar, Eliana - Gonzalez-Campos, Jose - Garrido, Ana - Algarra, Lorenzo - Salamero, Olga - Javier, de la Serna - Sayas, Maria Jose - Perez-Encinas, Manuel Mateo - Vives, Susana - Vidriales, Belen - Labrador, Jorge - Prado, Ana Ines - Celebrin, Lucia - Mayer, Jiří - Brioso, Joana - Almudena, de Laiglesia - Bergua, Juan Miguel - Amigo, Maria Luz - Rodriguez-Medina, Carlos - Polo, Marta - Pluta, Agnieszka - Cichocka, Edyta - Skarupski, Marek - Sanz, Miguel A - Wierzbowska, Agnieszka - Montesinos, Pau
PY  - 2024
TI  - Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience
JF  - Annals of hematology
VL  - 103
IS  - 2
SP  - 451-461
EP  - 451-461
PB  - Springer Verlag
SN  - 09395555
KW  - Acute promyelocytic leukemia
KW  - Second neoplasms
KW  - Chemotherapy based and chemotherapy free regimens
KW  - Risk factors
KW  - Outcomes
UR  - https://link.springer.com/article/10.1007/s00277-023-05582-y
N2  - The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs). We performed a retrospective analysis of 2670 unselected APL patients, treated with PETHEMA "chemotherapy based" and "chemotherapy free" protocols. Only de novo APL patients who achieved complete remission (CR) and completed the three consolidation cycles were enrolled into the analysis. Out of 2670 APL patients, there were 118 (4.4%) who developed s-NPLs with the median latency period (between first CR and diagnosis of s-NPL) of 48.0 months (range 2.8-231.1): 43.3 (range: 2.8-113.9) for s-MDS/AML and 61.7 (range: 7.1-231.1) for solid tumour. The 5-year CI of all s-NPLs was of 4.43% and 10 years of 7.92%. Among s-NPLs, there were 58 cases of s-MDS/AML, 3 cases of other hematological neoplasms, 57 solid tumours and 1 non-identified neoplasm. The most frequent solid tumour was colorectal, lung and breast cancer. Overall, the 2-year OS from diagnosis of s-NPLs was 40.6%, with a median OS of 11.1 months. Multivariate analysis identified age of 35 years (hazard ratio = 0.2584; p < 0.0001) as an independent prognostic factor for s-NPLs. There were no significant differences in CI of s-NPLs at 5 years between chemotherapy-based vs chemotherapy-free regimens (hazard ratio = 1.09; p = 0.932). Larger series with longer follow-up are required to confirm the potential impact of ATO+ATRA regimens to reduce the incidence of s-NPLs after front-line therapy for APL.
ER  -

SOBAS, Marta, Wanda KNOPINSKA-POSLUSZNY, Beata PIATKOWSKA-JAKUBAS, Flor GARCIA-ALVAREZ, Maria Elena Amutio DIEZ, Mar CABALLERO, David MARTINEZ-CUADRON, Eliana AGUIAR, Jose GONZALEZ-CAMPOS, Ana GARRIDO, Lorenzo ALGARRA, Olga SALAMERO, de la Serna JAVIER, Maria Jose SAYAS, Manuel Mateo PEREZ-ENCINAS, Susana VIVES, Belen VIDRIALES, Jorge LABRADOR, Ana Ines PRADO, Lucia CELEBRIN, Jiří MAYER, Joana BRIOSO, de Laiglesia ALMUDENA, Juan Miguel BERGUA, Maria Luz AMIGO, Carlos RODRIGUEZ-MEDINA, Marta POLO, Agnieszka PLUTA, Edyta CICHOCKA, Marek SKARUPSKI, Miguel A SANZ, Agnieszka WIERZBOWSKA and Pau MONTESINOS. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience. \textit{Annals of hematology}. New York: Springer Verlag, 2024, vol.~103, No~2, p.~451-461. ISSN~0939-5555. Available from: https://dx.doi.org/10.1007/s00277-023-05582-y.

Detailed Information on Publication Record